JP6805172B2 - ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 - Google Patents

ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 Download PDF

Info

Publication number
JP6805172B2
JP6805172B2 JP2017557324A JP2017557324A JP6805172B2 JP 6805172 B2 JP6805172 B2 JP 6805172B2 JP 2017557324 A JP2017557324 A JP 2017557324A JP 2017557324 A JP2017557324 A JP 2017557324A JP 6805172 B2 JP6805172 B2 JP 6805172B2
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
alkyl
mixture
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017557324A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515489A (ja
JP2018515489A5 (OSRAM
Inventor
ドミンゲス,セリア
シー. メイラード,マイケル
シー. メイラード,マイケル
エフ. ハウガン,アラン
エフ. ハウガン,アラン
デ ポエル,アマンダ ヴァン
デ ポエル,アマンダ ヴァン
ジェイ. ストット,アンドリュー
ジェイ. ストット,アンドリュー
エー. ラックハースト,クリストファー
エー. ラックハースト,クリストファー
エー. サヴィル−ストーンズ,エリザベス
エー. サヴィル−ストーンズ,エリザベス
ウィシャート,グラント
ウォール,マイケル
ブレッキア,ペルラ
イー. ジャーヴィス,レベッカ
イー. ジャーヴィス,レベッカ
Original Assignee
シーエイチディーアイ ファウンデーション,インコーポレーテッド
シーエイチディーアイ ファウンデーション,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーエイチディーアイ ファウンデーション,インコーポレーテッド, シーエイチディーアイ ファウンデーション,インコーポレーテッド filed Critical シーエイチディーアイ ファウンデーション,インコーポレーテッド
Publication of JP2018515489A publication Critical patent/JP2018515489A/ja
Publication of JP2018515489A5 publication Critical patent/JP2018515489A5/ja
Application granted granted Critical
Publication of JP6805172B2 publication Critical patent/JP6805172B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
JP2017557324A 2015-05-07 2016-05-06 ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 Active JP6805172B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562158363P 2015-05-07 2015-05-07
US62/158,363 2015-05-07
PCT/US2016/031335 WO2016179554A1 (en) 2015-05-07 2016-05-06 Histone deacetylase inhibitors and compositions and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2018515489A JP2018515489A (ja) 2018-06-14
JP2018515489A5 JP2018515489A5 (OSRAM) 2019-06-13
JP6805172B2 true JP6805172B2 (ja) 2020-12-23

Family

ID=57218014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017557324A Active JP6805172B2 (ja) 2015-05-07 2016-05-06 ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法

Country Status (11)

Country Link
US (2) US10053434B2 (OSRAM)
EP (1) EP3291810B1 (OSRAM)
JP (1) JP6805172B2 (OSRAM)
KR (1) KR20180002729A (OSRAM)
CN (1) CN107735088B (OSRAM)
AU (1) AU2016258188B2 (OSRAM)
CA (1) CA2984618C (OSRAM)
EA (1) EA036965B1 (OSRAM)
IL (1) IL255448B2 (OSRAM)
MX (1) MX378983B (OSRAM)
WO (1) WO2016179554A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3291809B1 (en) 2015-05-07 2021-08-25 CHDI Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
US10053434B2 (en) * 2015-05-07 2018-08-21 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
WO2018015447A1 (en) * 2016-07-22 2018-01-25 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
CN109627207A (zh) * 2018-12-17 2019-04-16 天津药明康德新药开发有限公司 一种3-(二氟甲氧基)哌啶盐酸盐的制备方法
WO2022174193A1 (en) * 2021-02-15 2022-08-18 The Research Foundation For The State University Of New York Radiolabeled compositions and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828171B1 (en) 2004-12-10 2014-03-12 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Heterocycle derivatives as histone deacetylase (hdac) inhibitors
KR101781663B1 (ko) 2010-01-13 2017-09-25 템페로 파마슈티칼즈, 인크. 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법
WO2013006408A1 (en) * 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
US9056843B2 (en) 2011-07-08 2015-06-16 Novartis Ag Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
WO2013009830A1 (en) * 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
SI2750677T1 (sl) 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
WO2013066835A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066833A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
ES2606630T3 (es) 2011-11-28 2017-03-24 Novartis Ag Derivados de trifluorometil-oxadiazol novedosos y su uso en el tratamiento de enfermedad
US9822058B2 (en) * 2012-04-05 2017-11-21 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US10053434B2 (en) * 2015-05-07 2018-08-21 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
EP3291809B1 (en) 2015-05-07 2021-08-25 CHDI Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
MX376585B (es) 2015-07-27 2025-03-07 Chong Kun Dang Pharmaceutical Corp Compuestos derivados de sulfamida de 1,3,4-oxadiazol como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos.
ES2935932T3 (es) 2015-07-27 2023-03-13 Chong Kun Dang Pharmaceutical Corp Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos
AU2016303891B2 (en) 2015-08-04 2019-08-01 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
EP3291810A4 (en) 2018-11-07
WO2016179554A1 (en) 2016-11-10
JP2018515489A (ja) 2018-06-14
AU2016258188A1 (en) 2017-11-23
IL255448A0 (en) 2017-12-31
BR112017023711A2 (pt) 2018-07-17
AU2016258188B2 (en) 2021-08-26
US10053434B2 (en) 2018-08-21
CN107735088A (zh) 2018-02-23
MX378983B (es) 2025-03-10
CA2984618C (en) 2024-01-09
EP3291810B1 (en) 2022-08-10
CN107735088B (zh) 2021-11-02
MX2017014300A (es) 2018-08-09
IL255448B2 (en) 2023-07-01
EP3291810A1 (en) 2018-03-14
HK1252487A1 (en) 2019-05-24
CA2984618A1 (en) 2016-11-10
EA036965B1 (ru) 2021-01-20
KR20180002729A (ko) 2018-01-08
EA201792247A1 (ru) 2018-06-29
US20190202795A1 (en) 2019-07-04
IL255448B1 (en) 2023-03-01
US20160326124A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
JP6782255B2 (ja) ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法
JP7644517B2 (ja) Kras突然変異型タンパク質阻害剤
JP6805172B2 (ja) ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法
BR112014030655B1 (pt) compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende
CN120077051A (zh) Kras抑制剂
KR20180110132A (ko) 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제
MX2013008629A (es) Inhibidores de histona desacetilasa y composiciones y metodos para su uso.
EP2976341A1 (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
CN109641894B (zh) 2-氮杂双环[3.1.0]己烷-3-酮衍生物及使用方法
TW201514135A (zh) 組蛋白去乙醯酶抑制劑及組成物,暨其使用之方法
CN113754635A (zh) 稠环类化合物及其制备方法和用途
CN119546607A (zh) Lrrk2抑制剂
HK1252487B (en) Histone deacetylase inhibitors and compositions and methods of use thereof
BR112017023711B1 (pt) Inibidores de histona deacetilase e composições e métodos de uso dos mesmos
WO2020207352A1 (zh) 三嗪酮并咪唑类化合物及其医药用途
HK1252489B (en) Histone deacetylase inhibitors and compositions and methods of use thereof

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200107

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200407

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201001

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201001

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20201009

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20201013

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201203

R150 Certificate of patent or registration of utility model

Ref document number: 6805172

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250